NRIX expansion of BTK degrader backed by Roche partnership
NRIX said its BTK degrader is progressing in CLL, CSU and MS, while a Roche partnership expands indications and provides financial backing. The pipeline also includes STAT6 and IRAK4 degraders with multiple upcoming readouts.